Unresolved questions on venous thromboembolic disease. Venous thromboembolism (VTE) management in obese patients. Consensus statement of the French Society of Vascular Medicine (SFMV) - 14/09/24
, Marjolaine Talbot b, Isabelle Gouin-Thibault c, Benjamin Espinasse d, e, Guillaume Mahe bon behalf the
SFMV
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Obesity is an alarming worldwide public health issue and is defined as a body mass index (BMI) of 30kg/m2 or more. It is considered as a risk factor for first thrombotic event and is associated with a significant risk of recurrence. Consequently, obese patients are often treated by anticoagulant therapy but data from randomised control trial are scarce. We will review in this narrative review the state of the art of the prescription of anticoagulant for the prevention and treatment of venous thromboembolism (VTE) in obese patients.
Le texte complet de cet article est disponible en PDF.Keywords : Obesity, Venous thromboembolism disease, Anticoagulants
Plan
Vol 49 - N° 3-4
P. 170-175 - septembre 2024 Retour au numéro
Article précédent
- Unresolved questions on venous thromboembolic disease. Therapeutic management of superficial vein thrombosis (SVT). Consensus statement of the French Society for Vascular Medicine (SFMV)
- Marie-Antoinette Sevestre, Marjolaine Talbot, Laurent Bertoletti, Dominique Brisot, Paul Frappe, Jean-Luc Gillet, Pierre Ouvry, SFMV
- Update on the diagnosis of recurrence of lower limb deep vein thrombosis. A Consensus statement of the French Society for Vascular Medicine (SFMV)
- Antoine Elias, Mario Maufus, Marie Elias, Marjolaine Talbot, Guillaume Mahe, Marie-Antoinette Sevestre, Gilles Pernod, French Society for Vascular Medicine (SFMV)
Bienvenue sur EM-consulte, la référence des professionnels de santé.